博瑞医药获机构调研，创新药管线进展受关注

Group 1 - The core focus of the news is on the recent attention received by Borui Pharmaceutical (688166) from institutional investors, particularly regarding its innovative drug pipeline progress [1] - Notable private equity firm Chongyang Investment and public fund Zhongyin Fund participated in the company's roadshow, emphasizing the advancements in the innovative drug pipeline [1] - The BGM0504 injection for type 2 diabetes and weight loss indications has completed patient enrollment for Phase III clinical trials in China, while the U.S. weight loss indication is in the process of finalizing its Phase III protocol, and Indonesia has initiated Phase III clinical trials [1] - The oral BGM0504 tablet is currently undergoing Phase I clinical trials in both China and the U.S. [1] - The company has also laid out multiple innovative pipelines, including GLP-1/GIP dual-target and BGM1812 injection, although these projects are still in early development stages, indicating potential risks [1] Group 2 - In the recent trading period from February 5 to February 11, 2026, Borui Pharmaceutical's stock price exhibited significant volatility [2] - As of February 11, the stock closed at 46.15 yuan, reflecting a daily decline of 1.77% and a cumulative weekly drop of approximately 1.83% [2] - The stock reached a peak price of 47.77 yuan on February 10 and a low of 45.60 yuan on February 4 [2] - On February 10, there was a net inflow of main funds amounting to 21.62 million yuan, but this shifted to a net outflow of 27.63 million yuan on February 11, indicating short-term capital divergence [2] - Overall, the stock's turnover rate remained around 1%, with a high valuation level (TTM price-to-earnings ratio of approximately 314 times), and its recent performance lagged behind the pharmaceutical and biotechnology sector, which experienced a slight decline of 0.32% during the same period [2]